Zirconium-89-labelled Rituximab PET-CT in Orbital Inflammatory Disease

Overview

Journal EJNMMI Res

Date 2019 Aug 1

PMID 31363937

Citations 9

Authors

Kamil G Laban

Rachel Kalmann

Roos J Leguit

Bart de Keizer

Affiliations

Soon will be listed here.

Abstract

Background: Orbital inflammatory diseases are a heterogenic group of conditions that often entail a difficult diagnostic process and many patients are treatment resistant. Inflammatory diseases can be visualized by Zirconium-89-labelled rituximab PET-CT (Zr-rituximab PET/CT). In this study, we describe our experience and possible potential of the Zr-rituximab PET/CT for diagnostic and therapeutic management of refractory orbital inflammation.

Results: Retrospectively, Zr-rituximab uptake was assessed and related to clinical data. The main outcome measures were the characteristics of the scan and the clinical relation of uptake with the diagnostic process and treatment effectivity. Twelve patients with thyroid eye disease (TED) and suspected idiopathic orbital inflammation (IOI) were scanned. Six patients had a strong Zr-rituximab uptake and showed a focal distribution within the lesion. Four patients (one TED, three IOI) responded well to rituximab treatment after a positive scan. Zr-rituximab PET/CT was essential to the diagnosis of optic nerve meningioma in one patient.

Conclusion: Zr-rituximab PET/CT has the potential to be a powerful tool for the detection of B cell-mediated disease within the orbit and ocular adnexa. This technique can be a valuable addition for diagnosing diseases around the eye and can potentially predict rituximab treatment response in patients with refractory inflammation.

Citing Articles

Emerging PET radiotracers for vascular imaging.

Peverelli M, Tarkin J Rheumatology (Oxford). 2025; 64(Supplement_1):i33-i37.

PMID: 40071433 PMC: 11897704. DOI: 10.1093/rheumatology/keae635.

Advances and challenges in immunoPET methodology.

Mohr P, van Sluis J, Lub-de Hooge M, Lammertsma A, Brouwers A, Tsoumpas C Front Nucl Med. 2024; 4:1360710.

PMID: 39355220 PMC: 11440922. DOI: 10.3389/fnume.2024.1360710.

Predictive markers for anti-inflammatory treatment response in thyroid eye disease.

Zhang H, Fan J, Qu J, Han Q, Zhou H, Song X Front Endocrinol (Lausanne). 2023; 14:1292519.

PMID: 38111706 PMC: 10726127. DOI: 10.3389/fendo.2023.1292519.

Current imaging methods for assessing Graves` orbitopathy activity with particular emphasis on FDG-PET.

Ochmann A, Winder M, Nalewajka-Kolodziejczak J, Chudek J Front Endocrinol (Lausanne). 2023; 14:1138569.

PMID: 37600686 PMC: 10435873. DOI: 10.3389/fendo.2023.1138569.

Rituximab for treatment of non-infectious and non-malignant orbital inflammatory disease.

Ng C, Sy A, Cunningham Jr E J Ophthalmic Inflamm Infect. 2021; 11(1):24.

PMID: 34448063 PMC: 8390731. DOI: 10.1186/s12348-021-00253-3.

References

Verel I, Visser G, Boellaard R, Stigter-van Walsum M, Snow G, van Dongen G . 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003; 44(8):1271-81. View

Shields J, Shields C, Scartozzi R . Survey of 1264 patients with orbital tumors and simulating lesions: The 2002 Montgomery Lecture, part 1. Ophthalmology. 2004; 111(5):997-1008. DOI: 10.1016/j.ophtha.2003.01.002. View

El Fassi D, Nielsen C, Hasselbalch H, Hegedus L . Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid. 2006; 16(7):709-10. DOI: 10.1089/thy.2006.16.709. View

Chastain J, Sindwani R . Anatomy of the orbit, lacrimal apparatus, and lateral nasal wall. Otolaryngol Clin North Am. 2006; 39(5):855-64, v-vi. DOI: 10.1016/j.otc.2006.07.003. View

Gordon L . Orbital inflammatory disease: a diagnostic and therapeutic challenge. Eye (Lond). 2006; 20(10):1196-206. DOI: 10.1038/sj.eye.6702383. View

Khanna D, Chong K, Afifiyan N, Hwang C, Lee D, Garneau H . Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology. 2009; 117(1):133-139.e2. PMC: 2814962. DOI: 10.1016/j.ophtha.2009.05.029. View

Silkiss R, Reier A, Coleman M, Lauer S . Rituximab for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2010; 26(5):310-4. DOI: 10.1097/IOP.0b013e3181c4dfde. View

Tran L, Huitema A, van Rijswijk M, Dinant H, Baars J, Beijnen J . CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis. Hum Antibodies. 2011; 20(1-2):29-35. DOI: 10.3233/hab20110239. View

Malviya G, Anzola K, Podesta E, Lagana B, Del Mastro C, Dierckx R . (99m)Tc-labeled rituximab for imaging B lymphocyte infiltration in inflammatory autoimmune disease patients. Mol Imaging Biol. 2011; 14(5):637-46. PMC: 3443359. DOI: 10.1007/s11307-011-0527-x. View

10.

van Dongen G, Poot A, Vugts D . PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol. 2012; 33(3):607-15. PMC: 3342498. DOI: 10.1007/s13277-012-0316-4. View

11.

Abell R, Patrick A, Rooney K, McKelvie P, McNab A . Complete resolution of idiopathic sclerosing orbital inflammation after treatment with rituximab. Ocul Immunol Inflamm. 2013; 23(2):176-9. DOI: 10.3109/09273948.2013.863943. View

12.

Suhler E, Lim L, Beardsley R, Giles T, Pasadhika S, Lee S . Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial. JAMA Ophthalmol. 2014; 132(5):572-8. PMC: 4321949. DOI: 10.1001/jamaophthalmol.2013.8179. View

13.

Klingenstein A, Haug A, Miller C, Hintschich C . Ga-68-DOTA-TATE PET/CT for discrimination of tumors of the optic pathway. Orbit. 2014; 34(1):16-22. DOI: 10.3109/01676830.2014.959185. View

14.

Stan M, Garrity J, Leon B, Prabin T, Bradley E, Bahn R . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. J Clin Endocrinol Metab. 2014; 100(2):432-41. PMC: 4318907. DOI: 10.1210/jc.2014-2572. View

15.

Boellaard R, Delgado-Bolton R, Oyen W, Giammarile F, Tatsch K, Eschner W . FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2014; 42(2):328-54. PMC: 4315529. DOI: 10.1007/s00259-014-2961-x. View

16.

Salvi M, Vannucchi G, Curro N, Campi I, Covelli D, Dazzi D . Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2014; 100(2):422-31. PMC: 4318899. DOI: 10.1210/jc.2014-3014. View

17.

Muylle K, Flamen P, Vugts D, Guiot T, Ghanem G, Meuleman N . Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. Eur J Nucl Med Mol Imaging. 2015; 42(8):1304-14. PMC: 4480335. DOI: 10.1007/s00259-015-3025-6. View

18.

de Jong A, Mous R, van Dongen G, Hoekstra O, Nievelstein R, de Keizer B . (89) Zr-rituximab PET/CT to detect neurolymphomatosis. Am J Hematol. 2016; 91(6):649-50. DOI: 10.1002/ajh.24328. View

19.

Dagi Glass L, Freitag S . Orbital inflammation: Corticosteroids first. Surv Ophthalmol. 2016; 61(5):670-3. DOI: 10.1016/j.survophthal.2016.01.005. View

20.

Mombaerts I, Rose G, Garrity J . Orbital inflammation: Biopsy first. Surv Ophthalmol. 2016; 61(5):664-9. DOI: 10.1016/j.survophthal.2016.03.002. View